Boston, MA 03/20/2014 (wallstreetpr) – Two positive stories steered up the shares of Prothena Corporation PLC (NASDAQ:PRTA), a clinical-stage biotech company by over 27% on Wednesday. First of all, the company declared that the Phase I interim data of NEOD001 will be submitted at the XIV International Symposium on Amyloidosis (ISA), scheduled to take place in Indianapolis during the last week of April. Secondly, the company got a back pat from an analyst at RBC Capital, who have upgraded the price target of the company from $38 to $52. This revision comes in context of NEOD001, which, according to the analyst has the potential to touch the sales of $500 million. It is noteworthy that NEOD001 had earned the status of orphan drug in 2012 by the FDA for treatingAL amyloidosis and AA (secondary). Later, it received the orphan drug status from the European Medicines Agency as well, in 2013.
First Solar, Inc. (NASDAQ:FSLR)‘s encouraging guidance took its shares to a peak on Wednesday. Although the outlook for 2014 did not appear so rosy, as earnings expectation being kept in between $2.20-$2.60 per share as against the Wall Street estimate of $3.12 per share. But, the company certainly projected a stronger outlook for 2015 and 2016, with earnings growth numbers estimated to touch $4.50-$6.00 and $3.50-$5.00 per share in those years, respectively. Specially, 2016 numbers are higher than the expectations set by the analysts, indicating that First Solar, Inc. (NASDAQ:FSLR) is looking forward to improve its margins in the forthcoming period.
Andatee China Marine Fuel Ser Corp (NASDAQ:AMCF), the China based oil and gas driller witnessed a steep climb in its shares since the past few months, which is considered as an outcome of the company’s effective measures taken of late. The company recently made a change in its management team, which includes appointment of Wang Hao as its CEO. Before assuming this role, Hao was with Andatee China Marine Fuel Ser Corp (NASDAQ:AMCF) as a CFO. Post this shift, the company chose MrQuan Zhang as an interim CFO.
